Literature DB >> 19278952

Copy number abnormalities, MYC activity, and the genetic fingerprint of normal B cells mechanistically define the microRNA profile of diffuse large B-cell lymphoma.

Cheng Li1, Sang-Woo Kim, Deepak Rai, Aswani R Bolla, Siddharth Adhvaryu, Marsha C Kinney, Ryan S Robetorye, Ricardo C T Aguiar.   

Abstract

MicroRNA (miRNA) deregulation contributes to cancer pathogenesis. However, analysis of miRNAs in diffuse large B-cell lymphoma (DLBCL) has been hindered by a focus on cell lines, limited number of miRNAs examined, and lack of copy number data. To address these restrictions, we investigated genomewide miRNA expression and copy number data in 86 DLBCLs. Permutation analysis showed that 63 miRNAs were recurrently disrupted in DLBCL, including highly expressed oncomirs not previously linked to chromosomal abnormalities. Further, using training and validation tumor groups, we defined a collection of miRNAs that robustly segregates DLBCLs into 3 subsets, which are independent of the cell-of-origin classification, extent of T-cell infiltrate, and tumor site. Instead, these unique miRNA-driven DLBCL subgroups showed markedly different MYC transcriptional activity, which explained the dominance of miRNAs regulated by MYC in their expression signatures. In addition, analysis of miRNA expression patterns of normal B cells and integration of copy number and expression data showed that genomic abnormalities and the genetic fingerprint of nonmalignant cells also contribute to the miRNA profile of DLBCL. In conclusion, we created a comprehensive map of the miRNA genome in DLBCL and, in the process, have uncovered and mechanistically elucidated the basis for additional molecular heterogeneity in this tumor.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19278952      PMCID: PMC3401058          DOI: 10.1182/blood-2009-01-202028

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  45 in total

1.  The interplay between the master transcription factor PU.1 and miR-424 regulates human monocyte/macrophage differentiation.

Authors:  A Rosa; M Ballarino; A Sorrentino; O Sthandier; F G De Angelis; M Marchioni; B Masella; A Guarini; A Fatica; C Peschle; I Bozzoni
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-03       Impact factor: 11.205

2.  Impaired microRNA processing enhances cellular transformation and tumorigenesis.

Authors:  Madhu S Kumar; Jun Lu; Kim L Mercer; Todd R Golub; Tyler Jacks
Journal:  Nat Genet       Date:  2007-04-01       Impact factor: 38.330

3.  HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity.

Authors:  Huafeng Zhang; Ping Gao; Ryo Fukuda; Ganesh Kumar; Balaji Krishnamachary; Karen I Zeller; Chi V Dang; Gregg L Semenza
Journal:  Cancer Cell       Date:  2007-05       Impact factor: 31.743

4.  SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma.

Authors:  Linfeng Chen; Stefano Monti; Przemyslaw Juszczynski; John Daley; Wen Chen; Thomas E Witzig; Thomas M Habermann; Jeffery L Kutok; Margaret A Shipp
Journal:  Blood       Date:  2007-11-15       Impact factor: 22.113

5.  Widespread microRNA repression by Myc contributes to tumorigenesis.

Authors:  Tsung-Cheng Chang; Duonan Yu; Yun-Sil Lee; Erik A Wentzel; Dan E Arking; Kristin M West; Chi V Dang; Andrei Thomas-Tikhonenko; Joshua T Mendell
Journal:  Nat Genet       Date:  2007-12-09       Impact factor: 38.330

6.  Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1.

Authors:  Jung-whan Kim; Ping Gao; Yen-Chun Liu; Gregg L Semenza; Chi V Dang
Journal:  Mol Cell Biol       Date:  2007-09-04       Impact factor: 4.272

7.  Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation.

Authors:  Carlos le Sage; Remco Nagel; David A Egan; Mariette Schrier; Elly Mesman; Annunziato Mangiola; Corrado Anile; Giulio Maira; Neri Mercatelli; Silvia Anna Ciafrè; Maria Giulia Farace; Reuven Agami
Journal:  EMBO J       Date:  2007-07-12       Impact factor: 11.598

8.  Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes.

Authors:  Changchun Xiao; Lakshmi Srinivasan; Dinis Pedro Calado; Heide Christine Patterson; Baochun Zhang; Jing Wang; Joel M Henderson; Jeffrey L Kutok; Klaus Rajewsky
Journal:  Nat Immunol       Date:  2008-03-09       Impact factor: 25.606

9.  Coordinated expression of microRNA-155 and predicted target genes in diffuse large B-cell lymphoma.

Authors:  Deepak Rai; Shailaja Karanti; Inkyung Jung; Patricia L M Dahia; Ricardo C T Aguiar
Journal:  Cancer Genet Cytogenet       Date:  2008-02

Review 10.  Mechanisms of MYC stabilization in human malignancies.

Authors:  Melissa R Junttila; Jukka Westermarck
Journal:  Cell Cycle       Date:  2007-12-29       Impact factor: 4.534

View more
  35 in total

Review 1.  Role of microRNAs in lymphoid biology and disease.

Authors:  Muller Fabbri; Carlo M Croce
Journal:  Curr Opin Hematol       Date:  2011-07       Impact factor: 3.284

Review 2.  Beyond R-CHOP and the IPI in large-cell lymphoma: molecular markers as an opportunity for stratification.

Authors:  Jason R Westin; Luis E Fayad
Journal:  Curr Hematol Malig Rep       Date:  2009-10       Impact factor: 3.952

3.  Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma.

Authors:  Christopher J Stasik; Hiroaki Nitta; Wenjun Zhang; Charles H Mosher; James R Cook; Raymond R Tubbs; Joseph M Unger; Tracy A Brooks; Daniel O Persky; Sarah T Wilkinson; Thomas M Grogan; Lisa M Rimsza
Journal:  Haematologica       Date:  2010-04       Impact factor: 9.941

4.  Complete characterization of the microRNAome in a patient with acute myeloid leukemia.

Authors:  Giridharan Ramsingh; Daniel C Koboldt; Maria Trissal; Katherine B Chiappinelli; Todd Wylie; Sunita Koul; Li-Wei Chang; Rakesh Nagarajan; Todd A Fehniger; Paul Goodfellow; Vincent Magrini; Richard K Wilson; Li Ding; Timothy J Ley; Elaine R Mardis; Daniel C Link
Journal:  Blood       Date:  2010-09-28       Impact factor: 22.113

5.  MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies.

Authors:  Ronit Vogt Sionov
Journal:  ISRN Hematol       Date:  2013-01-29

6.  Molecular distinctions between pediatric and adult mature B-cell non-Hodgkin lymphomas identified through genomic profiling.

Authors:  Karen E Deffenbacher; Javeed Iqbal; Warren Sanger; Yulei Shen; Cynthia Lachel; Zhongfeng Liu; Yanyan Liu; Megan S Lim; Sherrie L Perkins; Kai Fu; Lynette Smith; James Lynch; Louis M Staudt; Lisa M Rimsza; Elaine Jaffe; Andreas Rosenwald; German K Ott; Jan Delabie; Elias Campo; Randy D Gascoyne; Mitchell S Cairo; Dennis D Weisenburger; Timothy C Greiner; Thomas G Gross; Wing C Chan
Journal:  Blood       Date:  2012-02-28       Impact factor: 22.113

7.  Serum microRNAs in HIV-infected individuals as pre-diagnosis biomarkers for AIDS-NHL.

Authors:  Dharma R Thapa; Shehnaz K Hussain; Wen-Ching Tran; Gypsyamber Dʼsouza; Jay H Bream; Chad J Achenback; Velpandi Ayyavoo; Roger Detels; Otoniel Martínez-Maza
Journal:  J Acquir Immune Defic Syndr       Date:  2014-06-01       Impact factor: 3.731

8.  MicroRNA-124 links p53 to the NF-κB pathway in B-cell lymphomas.

Authors:  D Jeong; J Kim; J Nam; H Sun; Y-H Lee; T-J Lee; R C T Aguiar; S-W Kim
Journal:  Leukemia       Date:  2015-04-27       Impact factor: 11.528

9.  The regulatory network analysis of long noncoding RNAs in human colorectal cancer.

Authors:  Yuwei Zhang; Yang Tao; Yang Li; Jinshun Zhao; Lina Zhang; Xiaohong Zhang; Changzheng Dong; Yangyang Xie; Xiaoyu Dai; Xinjun Zhang; Qi Liao
Journal:  Funct Integr Genomics       Date:  2018-01-26       Impact factor: 3.410

Review 10.  Promising personalized therapeutic options for diffuse large B-cell Lymphoma Subtypes with oncogene addictions.

Authors:  James J Steinhardt; Ronald B Gartenhaus
Journal:  Clin Cancer Res       Date:  2012-06-27       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.